Patient Derived Cancer Model (PDCM) Finder

Information

  • Research Project
  • 10260591
  • ApplicationId
    10260591
  • Core Project Number
    U24CA253539
  • Full Project Number
    5U24CA253539-02
  • Serial Number
    253539
  • FOA Number
    RFA-CA-19-040
  • Sub Project Id
  • Project Start Date
    9/10/2020 - 4 years ago
  • Project End Date
    8/31/2025 - 8 months from now
  • Program Officer Name
    LI, JERRY
  • Budget Start Date
    9/1/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    7/26/2021 - 3 years ago

Patient Derived Cancer Model (PDCM) Finder

Project Summary - Patient Derived Cancer Model (PDCM) Finder An area of significant growth in cancer research is the diversity and volume of low passage human cancer cell lines, three-dimensional organoid cultures and patient-derived tumor xenografts (PDX) known as Patient Derived Cancer Models (PDCM). This project will therefore aggregate, harmonize and integrate diverse PDCM data, extending our previous resource PDX Finder by inclusion of novel models, making these FAIR (Findable, Accessible, Interoperable, Reusable) compliant and cloud accessible, for example in the NCI Research Commons. PCDM Finder will address challenges with searching over many repositories for models, incompatible standards that make analysis and reuse of models difficult, molecular datasets annotated with insufficient information that prevent cloud-based analyses and the need for more community awareness in providing FAIR- compliant data to maximize the impact of their work. To address these challenges, PDCM Finder has 3 tasks: 1) Enable cancer researchers to Find and Access models by enhancing our current resource to deliver the PDCM Finder, 2) Aggregate and Integrate PDCM datasets to ensure Interoperability and Reusability for the NCI Cancer Research Commons, and 3) Perform targeted community outreach during all stages of the project to determine and prioritize requirements, guide development and promote the PDCM Finder resource. The expected outcomes are users will be able to find, group and locate PDCM models of all types based on community defined attributes (e.g. diagnosis, oncogenic mutation); explore and download molecular data summaries and drug response data from the PDCM portal; aggregate and analyze harmonized PDCM molecular datasets on cloud based analysis platforms. This will accelerate cancer research by allowing doctors and researchers to find PDCM data that best matches their patients and/or research questions and explore new therapeutic avenues for patients.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    U24
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    492971
  • Indirect Cost Amount
    39438
  • Total Cost
    532409
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:532409\
  • Funding Mechanism
    OTHER RESEARCH-RELATED
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    EUROPEAN MOLECULAR BIOLOGY LABORATORY
  • Organization Department
  • Organization DUNS
    321691735
  • Organization City
    HEIDELBERG
  • Organization State
  • Organization Country
    GERMANY
  • Organization Zip Code
    69117
  • Organization District
    GERMANY